Corcept's Korlym Revenue Surge Faces Immediate Threat from Teva Generic Court Ruling

What happened

Korlym sales rose 13% year-over-year in 2025, driving Corcept's revenue growth and prompting management to project 2026 revenues of $900M-$1B. However, a court ruling favoring Teva's generic version of Korlym introduces significant competitive pressure that could accelerate sales erosion. Corcept remains heavily reliant on Korlym, which already faces authorized generic competition and reimbursement challenges, as noted in the DeepValue report. The company's diversification hopes rest on relacorilant's FDA decision for Cushing's by end of 2025, but this is a binary regulatory risk. Despite current profitability, the stock's high valuation (P/E ~73x) and low margin of safety make it vulnerable to any pipeline setbacks or faster-than-expected generic adoption.

Implication

The 13% sales increase in 2025 is a positive signal but may be short-lived due to the Teva court ruling, which could lead to quicker market share loss and pricing pressure. Management's 2026 revenue guidance of $900M-$1B appears optimistic and should be viewed skeptically, given the heightened risk of downward revisions from generic competition. Corcept's heavy dependence on Korlym exacerbates its vulnerability, with authorized generics already in play and potential for broader erosion impacting cash flows. Relacorilant's approval is critical for diversification, but regulatory uncertainty and execution risks mean success is far from guaranteed, keeping the investment thesis binary. With a P/E of ~73x and FCF yield of ~2.2%, the stock offers limited downside protection, reinforcing the need for patience until pipeline catalysts materialize or Korlym dynamics stabilize.

Thesis delta

The DeepValue report's HOLD stance remains appropriate, but the Teva court ruling amplifies the near-term risk of faster-than-expected Korlym erosion, which was already a key concern. This development tightens the timeline for monitoring quarterly revenue trends and the FDA decision on relacorilant, potentially skewing the risk/reward balance slightly more negative if generic adoption accelerates rapidly.